The Association of the British Pharmaceutical Industry has been working on changes to the ABPI Code of Practice for the Pharmaceutical Industry and the PMCPA Constitution and Procedure.
The proposed changes follow work done by a group chaired by Hugo Fry, Sanofi UK Country Chair and General Manager Sanofi Pasteur, established by the ABPI Board, as well as feedback from member companies, patient organisations and others.
The requirements of the ABPI Code of Practice and its administration by the PMCPA demonstrate the commitment of the pharmaceutical industry to benefiting patients by operating in a professional, ethical and transparent manner. …
Read more of this article
Please join 
Musculoskeletal conditions are common – we all know that. But it hadn’t struck me until recently just how common compared to other long term conditions. 17 million people in the UK have an MSK condition. Compare that with the 850,000 with dementia and think about how much we talk about dementia. It’s a similar picture for other conditions: diabetes, 3.5 million people, cardiovascular, 7 million. Only mental health exceeds the prevalence of MSK conditions.
NASS will be returning to Northern Ireland for a Community Engagement Conference on 27 October 2018.
As you are hopefully already aware, a clinically-led programme called London Choosing Wisely is underway to develop pan-London policies for eight treatment areas, to ensure patients across London have consistent access to treatment that improves their health, based on the latest available evidence. Full details about the programme, including a list of Frequently Asked Questions, are available online via: 
The National Institute for Health and Care Excellence (NICE) produces guidance on the most effective ways to prevent, diagnose and treat disease and ill health, and provide social care support. Their guidance is based on research evidence and takes into account the views of people working in or using relevant services, and other stakeholder groups.